Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein in 'good cholesterol' may be a key to treating pulmonary hypertension

28.08.2014

Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.

A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.


This images shows the differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent (left) treated with the HDL peptide. Note the very narrowed lung artery, and thick walls and larger chamber of the right heart in the diseased animal and improvements with 4F peptide treatment.

Credit: UCLA


This image shows the differences in the structure of a small lung artery (top row) and heart (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent (right) treated with the molecule microRNA193. Note the very narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with microRNA-193 treatment.

Credit: UCLA

Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called "good" cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents' heart and lung function.

The study appears in the current online edition of the peer-reviewed journal Circulation.

A rare progressive condition, pulmonary hypertension can affect people of all ages. The disease makes it harder for the heart to pump blood through these vital organs, which can lead to heart failure.

"Our research helps unravel the mechanisms involved in the development of pulmonary hypertension," said Dr. Mansoureh Eghbali, the study's senior author and an associate professor of anesthesiology at the David Geffen School of Medicine at UCLA. "A key peptide related to HDL cholesterol that can help reduce these oxidized lipids may provide a new target for treatment development."

Lipids such as fatty acids become oxidized when they are exposed to free radicals — tiny particles that are produced when the body converts food into energy -- or when they are exposed to pollution, and in numerous other ways.

Although researchers have known that oxidized lipids played a role in the development of atherosclerosis and other vascular diseases, the UCLA team discovered higher-than-normal levels of oxidized proteins in rodents with pulmonary hypertension.

The UCLA researchers also knew that apoA-1, a protein that is a key component of HDL cholesterol, can reduce oxidized lipids, so they used a small peptide called 4F that mimics the action of apoA-1 and found that the 4F not only decreased the levels of oxidized lipids in the rodents, but also improved their heart and lung function. Specifically, the peptide restored the altered expression of a key molecule called micro ribonucleic acid (microRNA-193), which targets the action of essential enzymes involved in the production of oxidized lipids.

"The increased amounts of these oxidized lipids due to pulmonary hypertension keeps the expression of this molecule under check, which aggravates symptoms of the disease," said first author Dr. Salil Sharma, a UCLA postdoctoral researcher in anesthesiology.

By restoring the expression of microRNA-193 to its full potential, the researchers reduced the amount of oxidized lipids in the animals with pulmonary hypertension.

One of the hallmarks of pulmonary hypertension is a proliferation of smooth muscle cells in the lungs, which is harmful because it narrows the lungs' small blood vessels.

Additionally, Eghbali's team found reduced levels of microRNA-193 in the blood and lung tissue of human patients with the disease and discovered that they could slow the proliferation of the smooth muscle cells by increasing levels of microRNA-193 in the cells that had been isolated from these patients' lungs.

Further research will be required to test the potential of the HDL-related peptide and microRNA-193 in human disease, and to better understand how the levels of oxidized lipids in the blood may correlate to disease severity in people with pulmonary arterial hypertension.

###

The study was funded in part by the American Heart Association, the National Institute of Health, the UCLA Clinical and Translational Science Institute and the Iris Cantor–UCLA Women's Health Center executive advisory board.

The study's other authors were Dr. Soban Umar, Andrea Iorga, Gabriel Wong, Denise Mai and Dr. Kaveh Navab of the division of molecular medicine at UCLA's department of anesthesiology; David Meriwether, Dr. Mohamad Navab, Dr. Alan Fogelman and Dr. Srinivasa Reddy of the division of cardiology at UCLA's department of medicine; Dr. David Ross of the division of pulmonary critical care medicine at the David Geffen School of Medicine at UCLA's department of medicine; and Francois Potus, Sandra Breuils-Bonnet, Dr. Steve Provencher and Dr. Sébastien Bonnet of Laval University in Québec, Canada.

All of the intellectual property for the HDL-related peptide is owned by the University of California Regents and managed by the UCLA Office of Intellectual Property and Industry Sponsored Research. The technology is currently licensed exclusively to Bruin Pharma Inc. Fogelman, Navab and Reddy are principals in Bruin Pharma, and Fogelman is an officer in the company. Other disclosures are listed in the manuscript.

Rachel Champeau | Eurek Alert!
Further information:
http://www.uclahealth.org/

Further reports about: HDL Health Medicine Protein UCLA blood cholesterol hypertension lung pulmonary

More articles from Health and Medicine:

nachricht Improving memory with magnets
28.03.2017 | McGill University

nachricht Graphene-based neural probes probe brain activity in high resolution
28.03.2017 | Graphene Flagship

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

NASA spacecraft investigate clues in radiation belts

28.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>